Does Nebraska Medicaid Cover Wegovy or Zepbound?
Nebraska (NE) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does Nebraska Medicaid cover weight-loss GLP-1s, has Nebraska expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
Nebraska Medicaid GLP-1 coverage: what the state's own documents say
Nebraska Medicaid fee-for-service covers Wegovy only for cardiovascular risk reduction or MASH (oral tablets for cardiovascular risk only) and Zepbound only for moderate-to-severe sleep apnea, with no weight-loss pathway, and its preferred drug list GLP-1 class contains only diabetes agents. A 2024 bill to require obesity coverage (LB 907) was indefinitely postponed on April 18, 2024.
Checked September 20, 2026 against: nebraska.fhsc.com, nebraska.fhsc.com, nebraska.fhsc.com, nebraskalegislature.gov.
Nebraska state employee health plan: what the plan's own documents say
Nebraska's state employee plan excludes weight-loss drugs from the pharmacy benefit: the 2025-26 UnitedHealthcare plan document named GLP-1 and GLP-1/GIP drugs with a weight-loss indication as not covered for any condition, and the 2026-27 Blue Cross and Blue Shield of Nebraska booklets exclude 'diet, weight loss or appetite suppressant drugs'.
Checked September 20, 2026 against: das.nebraska.gov, das.nebraska.gov.
Notable insurers active in Nebraska (not independently verified): Blue Cross Blue Shield of Nebraska, UnitedHealthcare, Aetna.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (Nebraska is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the Nebraska-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for Nebraska residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Nebraska carrier coverage details
National carriers active in Nebraska (this list is not independently verified). Drill into each carrier's prior-auth requirements, formulary, and appeal playbook.
Frequently asked questions
Does Nebraska Medicaid cover Wegovy or Zepbound for weight loss?
No. Nebraska Medicaid fee-for-service covers Wegovy only for cardiovascular risk reduction or MASH (oral tablets for cardiovascular risk only) and Zepbound only for moderate-to-severe sleep apnea, with no weight-loss pathway, and its preferred drug list GLP-1 class contains only diabetes agents. A 2024 bill to require obesity coverage (LB 907) was indefinitely postponed on April 18, 2024. This was checked against Nebraska's own documents on September 20, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has Nebraska expanded Medicaid under the ACA?
Yes - Nebraska has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the Nebraska state employee health plan cover Wegovy or Zepbound?
No. Nebraska's state employee plan excludes weight-loss drugs from the pharmacy benefit: the 2025-26 UnitedHealthcare plan document named GLP-1 and GLP-1/GIP drugs with a weight-loss indication as not covered for any condition, and the 2026-27 Blue Cross and Blue Shield of Nebraska booklets exclude 'diet, weight loss or appetite suppressant drugs'. This was checked against Nebraska's own plan documents on September 20, 2026; plan terms are reset each plan year, so confirm with your plan before relying on it.